Login to Your Account


Phase I scrutiny
The snail-horn sensitivity of investors in chimeric antigen receptor T cell (CAR-T) immunotherapy made itself known as data continue to spill from the American Association for Cancer Research (AACR) meeting in Philadelphia, with early results offered by Novartis AG sending ripples across the space. more »

Opinion


Partners in Focus